Finanzen von Obsidian Therapeutics, Inc. Common Stock (OBX)OBXObsidian Therapeutics, Inc. Common Stock

In the context of the broader market, OBX competes directly with industry leaders such as SVRA and AKTS. With a market capitalization of $860.50M, it holds a significant position in the sector. When comparing efficiency, OBX's gross margin of N/A stands against SVRA's N/A and AKTS's 100.00%. Such benchmarking helps identify whether Obsidian Therapeutics, Inc is trading at a premium or discount relative to its financial performance.

The company is expected to turn profitable by Q4 2025 with a projected net income of $65,358,000, indicating a significant turnaround from current losses.